AKZO.Y delivered a Q1 earnings beat last week. The stock didn't hold the gain — and the cost of betting against it is now rising fast.
The lending market tells the more interesting story this week. Cost to borrow climbed to 6.18% on Tuesday, its highest level since early March and up nearly 38% from where it opened seven days ago. That steady grind higher in borrowing costs points to growing demand for short positions even as the absolute number of shares shorted on the ADR remains small. Availability on the OTC line has tightened in step with the cost move, though the primary squeeze pressure on AKZA in Amsterdam remains the more meaningful signal for institutional positioning. The ORTEX short score of 36 is moderate — off its April highs above 45 — and sits in a relatively benign percentile, suggesting the borrow market is becoming more active without yet flashing a crowded-short warning.
The Q1 print itself was a quiet positive. AkzoNobel beat EPS estimates by five cents, and shareholders approved all resolutions at the April 24 AGM. The stock ticked up around 1.2% on results day before giving back that gain and then some — Tuesday's 4.4% drop erased the week's earlier recovery, leaving the shares down 2.9% over the past five sessions at $19.59 on the OTC. That puts the ADR down 13.6% year-to-date, even after a 4.8% bounce over the past month. The mismatch between a solid operational update and a falling share price is the central tension right now.
The analyst community remains broadly constructive. The ORTEX factor score for analyst recommendation difference ranks at just 7 — near the bottom of the universe — which means consensus is clustered toward the positive end relative to the stock's current positioning. Analyst return potential on the Amsterdam shares is quoted at 22.4%, a meaningful implied upside from current levels. The dividend score of 74 reflects a well-covered payout, and the 12-month forward yield approaches 3.9%. Days-to-cover at 23 days is an unusually long runway for a specialty chemicals name, though that partly reflects thinner trading on the OTC line rather than purely a surge in short positions.
Ownership dynamics add another layer. Cevian Capital, the Swedish activist fund, holds 10.1% of the company — a position it built aggressively through 2025, adding more than 12 million shares by December. Artisan Partners entered with a similarly large allocation, acquiring 8.5 million shares by January 2026. Alongside steadier hands in BlackRock, Vanguard, and T. Rowe Price, the register is stacked with active and passive names who collectively hold well above 40% of the float. That kind of ownership concentration acts as a natural buffer against extended short pressure — shares are harder to locate when the major holders aren't lending, which is consistent with the rising cost to borrow.
The next scheduled event is a Q2 results date of July 22. Between now and then, the focus is on whether stalled US refinish demand — flagged in the trade press as a soft spot in the Q1 report — broadens into other geographies, or whether AkzoNobel's pricing discipline holds margins through a softening demand environment. The divergence between a constructive earnings result and a deteriorating OTC price is the setup to watch into the summer.
See the live data behind this article on ORTEX.
Open AKZO.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
